Trial purpose
Cancer treatment
Tumor type
Multi-Cancer
Age
18+
Clinical summary
Summary
This trial has two phases: A Dose Escalation Phase and a Dose Expansion Phase.
In the Dose Escalation Phase, ATG-101 will be administered intravenously (via IV) once every 21 days in increasing doses until the recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD) or biologically optimal dose is determined. In the Dose Expansion Phase, ATG-101 will be administered at the dose level determined in the Dose Escalation Phase.
Please note: Austin Health are currently only recruiting people with Glioblastoma tumours.
Conditions
This trial is treating people with metastatic or advanced solid cancers and mature B-cell Non-Hodgkin Lymphoma
Eligibility
Inclusion
- Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
- Aged at least 18 years as of the date of consent.
- Histological or cytological confirmation of a solid tumor, and has progressed despite standard therapy, or is intolerant to standard therapy, or has a tumor for which no standard therapy exists or for which standard therapy is not considered adequate. Estimated life expectancy of a minimum of 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Female and male subjects should be using adequate contraceptive measures as requested.
Exclusion
- Subjects with CNS tumors or known CNS metastases will be excluded.
- Prior ATG-101 administration or a 4-1BB agonist.
- Prior anti-tumor systemic therapy within 21 days(a period of 5 'half- lives') of the first dose of study treatment.
- Radiotherapy with a wide field of radiation within 28 days.
- With the exception of alopecia, any unresolved toxicities from prior therapy greater than Grade 1 (CTCAE v5.0) at the time of ICF signature.
- Active infection, including hepatitis B and/or hepatitis C.
- Have uncontrolled intercurrent illness, including but not limited to:
- Inadequate bone marrow reserve or organ function.
- History of hypersensitivity or history of allergic reactions attributed to drugs with a similar chemical or biologic structure or class to ATG-101.
- Prior organ allograft transplantations.
- Pregnant or nursing females.
- Have a history of another primary malignancy within 3 years prior to starting study treatment. Exceptions are as follows: the disease under study; adequately treated basal or squamous cell carcinoma of the skin; cancer of the cervix in situ, etc.
- In the opinion of the investigator, subject's complications or other conditions may affect protocol compliance or may be unsuitable for participation in the study.
Inclusion
- You have had treatment, but your cancer has come back (relapsed or recurrent).
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- Your cancer has not spread to other parts of the body (localised).
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Antengene Biologics Limited
Scientific Title
A First-in-Human Phase I Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information